• Oculis Holding AG OCS.OQ reported a quarterly adjusted loss of 42 rappen​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -67 rappen. The mean expectation of ten analysts for the quarter was for a loss of 42 rappen per share. Wall Street expected results to range from -64 rappen to -18 rappen per share.

• Revenue rose 13,600% to CHF411.00 thousand from a year ago; analysts expected CHF131.15 thousand.

• Oculis Holding AG's reported EPS for the quarter was a loss of 42 rappen​.

• The company reported a quarterly loss of CHF23.51 million.

• Oculis Holding AG shares had risen by 43.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Oculis Holding AG is $45.50, about 37.1% above its last closing price of $28.61

This summary was machine generated from LSEG data March 3 at 10:01 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)